EPSILOGEN
8.7.2024 08:01:30 CEST | Business Wire | Press release
Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces that the Clinical Trial Application for the Phase Ib trial of MOv18 IgE has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA).
The Phase Ib study is expected to initiate later in 2024 and will evaluate the efficacy of MOv18 IgE in patients with platinum-resistant ovarian cancer (PROC).
Dr Tim Wilson, Chief Executive Officer of Epsilogen, said: “This CTA is another significant milestone for Epsilogen and the clinical development of MOv18 IgE. We look forward to progressing MOv18 IgE into a Phase Ib efficacy study later this year as we continue to demonstrate the potential of IgE antibodies as a new, differentiated class of cancer treatments.”
About MOv18 IgE
MOv18 IgE is an immunoglobulin E (IgE) antibody targeting the folate receptor alpha (FR alpha) antigen. FR alpha is present on a variety of cancers including ovarian, endometrial, lung and triple negative breast cancer. Epsilogen has successfully completed a Phase I safety study of MOv18 IgE in PROC patients. The results of the study, published in Nature Communications, found MOv18 IgE to be safe and well tolerated, with evidence of anti-tumour activity observed. Epsilogen, alongside its partner Lonza, also announced the successful completion of large-scale Good Manufacturing Practice (GMP) manufacturing of MOv18 IgE earlier this year.
About the Phase Ib study
The Phase Ib study is designed to confirm the safety and tolerability of MOv18 IgE and demonstrate efficacy in PROC. Following the dose escalation, an expansion cohort will be recruited to make a preliminary assessment of the anti-tumour activity of MOv18 IgE at a selected dose. In addition, delay to disease progression will be assessed along with a number of translational elements to generate further understanding of MOv18 IgE in the study population.
About Epsilogen Ltd
Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer. IgE’s natural function is to provide immunological defence against certain parasites. This functionality makes it an ideal treatment of solid tumours due to its strong potency, enhanced tumour access and long tissue half-life.
Epsilogen’s lead product candidate, MOv18 IgE, is the first therapeutic IgE antibody to enter the clinic and encouraging data from a completed Phase I trial demonstrated MOv18 IgE to be safe and well tolerated with early signs of clinical activity. Epsilogen has recently successfully completed large scale GMP manufacture of MOv18 IgE (the first time this has been achieved for an IgE antibody) and will initiate a Phase Ib trial in platinum-resistant ovarian cancer patients later this year. The company is also developing a pipeline of IgE therapies in oncology as well as proprietary platforms including IgE bispecifics and unique IgE/IgG combination antibody molecules (IgEGs) with enhanced functionality.
Epsilogen began operations in 2017 as a spin-out of King’s College London and has attracted venture capital financing from Epidarex Capital, Novartis Venture Fund, 3B Future Health, British Patient Capital, ALSA Ventures and Schroders Capital amongst others. Find out more at epsilogen.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240707808760/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Festo, Softcat, ANS Group and SCC Demonstrate the Business Impact of AI-Powered Observability5.11.2026 09:00:00 CET | Press release
LogicMonitor's 2026 EMEA Elevate Award winners are reducing alert noise, accelerating incident detection and transforming IT operations with AI and automation LogicMonitor®, the AI-first platform for Autonomous IT, announced the 2026 Elevate Award winners today at its Elevate Community Conference in London. The annual awards recognize LogicMonitor customers and partners that are achieving measurable business and operational outcomes through AI-powered observability. From consolidating 90% of monitoring tools and reducing alert noise by 85% to cutting observability case volumes by 45%, this year's EMEA winners demonstrate how organizations are simplifying complex IT environments, improving resilience and putting AI-powered operations into practice. “This year's EMEA Elevate Award winners are proving that the path to Autonomous IT starts with real, measurable improvements in how organizations operate,” said John Grosshans, President of Field Operations, LogicMonitor. “They're reducing co
New AGCO Power CORE Engines to Power Two New Tractors at EIMA 20265.11.2026 07:00:00 CET | Press release
AGCO Power’s CORE engine technology will be represented at EIMA International 2026 in new tractors from Massey Ferguson and Valtra. Developed from a clean sheet, the CORE engine family provides a next-generation platform for demanding off-highway applications. At EIMA International in Bologna, Italy, on November 10–14, 2026, visitors will be able to see how the AGCO Power CORE75 engine platform supports the different requirements of the Massey Ferguson new model MF 7S MARK 2 range and Valtra’s new sixth-generation Valtra T Series. A CORE75 engine will also be on display at the Valtra stand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104588496/en/ Massey Ferguson 7S MARK 2 The CORE engine family represents AGCO Power’s investment in a completely new engine platform at a time when few manufacturers are making comparable commitments to off-highway combustion engine development. The CORE engine family is designed to meet
SPIE Announces 2027 Prism Awards Finalists for Best Photonics Products4.11.2026 21:22:00 CET | Press release
The 19th annual competition recognizes groundbreaking technologies around the globe SPIE, the international society for optics and photonics, has announced finalists in the seven categories for the 2027 Prism Awards, which recognize remarkable new photonics products on the market. Winners will be announced during the awards ceremony at SPIE Photonics West on 3 February 2027 in San Francisco, California. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104613876/en/ SPIE has announced the finalists for the 2027 SPIE Prism Awards, which recognize optics and photonics innovations. Recipients will be announced at the awards ceremony on 3 February 2027 at SPIE Photonics West. During the Prism Awards, SPIE will also announce the winner of the SPIE Catalyst Award, honoring a for-profit company with social or environmental programs that have made significant advances in workplace opportunity, community engagement, or environmental
Every Critical System Should Have a Backup: Elliptic Opens Up Fast Track Monitoring to the Crypto Industry4.11.2026 21:07:00 CET | Press release
Fast Track Monitoring, powered by Elliptic Lens, gives compliance teams screening continuity when they need it most Elliptic, the leader in on-chain risk management, is making Fast Track Monitoring available to firms with digital assets exposure as a back up screening option for firms that need business continuity, if their primary screening service is unavailable and they need a second option. Criminals are increasingly using AI to scale their attacks, so on-chain risk now moves at machine speed. Compliance teams need the broadest range of options to keep screening every wallet and transaction, and a second screening provider builds resilience into any on-chain risk management approach. Elliptic recommends every business has one in place. Organizations that rely on a single screening vendor can also still need a second option. Fast Track Monitoring gives compliance teams real-time wallet and transaction screening powered by Elliptic Lens, with a clear, explainable risk score on every
Smartsheet Adds New AI Agents, Integrations and Security Advancements at ENGAGE 20264.11.2026 19:00:00 CET | Press release
New AI advancements take over status reports and routine follow-ups, powered by 20 years of workflow intelligence seeing how work happens and where it drifts, with enterprise security and governance built-in Smartsheet, the AI-powered enterprise work management platform, today announced new platform capabilities at ENGAGE 2026, its annual customer conference. The company introduced new AI agents, agentic workflows, system integrations and security controls built to end execution drift: the costly gap between what an organization sets out to deliver and what it actually delivers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104562370/en/ Today, Smartsheet introduced new AI agents, agentic workflows, system integrations and security controls built to end execution drift. AI has helped teams move faster, but it is also widening execution drift. As AI agents join people, partners and systems in doing the work, three problem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom